GVS (GVS) Investor update summary

Upward guidance and financial outlook

• 2026 revenue guidance raised to mid-single-digit organic growth, with EBITDA margin expected to expand by 50–100 basis points versus 2025, targeting 26% in 2026 and 27% by 2028.

• Leverage ratio is projected to improve from 2.0x at end-2026 to 1.0x by 2028, driven by strong operating cash flow, disciplined capital management, and margin expansion.

• No M&A activity planned through at least 2028, with focus on organic growth, margin improvement, and operational excellence.

• Free cash flow is projected at €50–60 million per year, with CapEx at 7% of sales and net financial costs stable due to mostly fixed-rate debt.

• Assumptions include 5% organic growth, 1.5% pricing, flat raw material costs, and 2.5% inflation on other costs.

Business segment strategies and growth drivers

• MedTech targets mid-single-digit growth, leveraging commercial synergies, new product launches, and a dedicated salesforce for bioprocessing and pharmaceutical bags.

• Transfusion medicine aims to increase market share from 6.5% to 8% by 2028, focusing on collection products, global platform scaling, and expansion in the U.S. and Asia-Pacific.

• Safety division expects high-single-digit growth, driven by product innovation (e.g., Elipse face mask, full face mask) and geographic expansion, especially in the U.S. and emerging markets.

• Life Science is reorganized with a broader filtration portfolio and new distribution agreements, targeting high-single-digit growth and pharma customer penetration.

• Energy & Mobility stabilizes legacy business and pursues growth in electronics, venting, and hydrogen membranes, with initial commercial hydrogen sales expected in 2027.

Product innovation and market positioning

• New product launches and portfolio expansion are key to gaining market share, with innovation in both high-value and volume segments.

• Safety products, especially RPE and full face masks, are positioned as best-in-class, with U.S. certification unlocking further growth.

• Hydrogen membrane business receives positive customer feedback, with a market opportunity that could grow 10x by 2030, especially in Asia.

• Bioprocessing and humanoid applications are seen as natural extensions of existing capabilities, requiring minimal new development.

• Growth is driven by commercial synergies, market share recovery, new distribution agreements, and improved order intake.